GM04391
LCL from B-Lymphocyte
Description:
FABRY DISEASE
GALACTOSIDASE, ALPHA; GLA
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases Lysosomal Storage Diseases |
Class |
Disorders of Lipid Metabolism |
Biopsy Source
|
Peripheral vein
|
Cell Type
|
B-Lymphocyte
|
Tissue Type
|
Blood
|
Transformant
|
Epstein-Barr Virus
|
Sample Source
|
LCL from B-Lymphocyte
|
Race
|
White
|
Relation to Proband
|
proband
|
Confirmation
|
Clinical summary/Case history
|
ISCN
|
46,XY
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Nucleoside Phosphorylase, Glucose-6-Phosphate Dehydrogenase, and Lactate Dehydrogenase Isoenzyme Electrophoresis |
|
alpha-galactosidase |
According to the submitter, biochemical test results for this subject showed decreased enzyme activity. EC Number: 3.2.1.22; 0% activity. |
|
Gene |
GLA |
Chromosomal Location |
Xq22 |
Allelic Variant 1 |
300644.0018; FABRY DISEASE |
Identified Mutation |
ASN215SER; Eng et al. (1993) and Davies et al. (1993) have described an AAT-to-AGT mutation at codon 215 of exon 5 resulting in an asn215-to-ser substitution. The patients had mild forms of Fabry disease.
|
Remarks |
Cardiac variant; mild clinical manifestations; residual alpha-galactosidase A activity in fibroblasts and WBC; no activity in plasma; 46,XY; donor subject is hemizygous for an A>G transition in exon 5 of the GLA gene (AAT>AGT) resulting in the substitution of serine for asparagine at codon 215 [Asn215Ser (N215S)] |
Split Ratio |
1:4 |
Temperature |
37 C |
Percent CO2 |
5% |
Medium |
Roswell Park Memorial Institute Medium 1640 with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not Inactivated |
Substrate |
None specified |
Subcultivation Method |
dilution - add fresh medium |
Supplement |
- |
|
|